Gilead announces management changes and appointments
Gilead Sciences announced that Gregg Alton has been appointed Chief Patient Officer, a newly created role that will facilitate access to the company's medicines and increase focus on reaching patients. The company also announced that Diana Brainard has been promoted to Senior Vice President, HIV and Emerging Viral Infections, and that Andrew Cheng Chief Medical Officer, has decided to leave Gilead to pursue another opportunity. Alton joined the company nearly 20 years ago and was the architect of its access program, which has enabled Gilead's HIV medicines to reach more than 11 million people in the developing world. He has helped shape the organization in a number of executive positions, including as general counsel, and more recently, leading the company's international commercial operations and corporate affairs groups. Brainard joined Gilead in 2010. She has extensive training and experience in immunology, infectious diseases and drug development. Under her leadership, Gilead received regulatory approval of four chronic hepatitis C virus therapies in a period of less than four years. She was promoted to Vice President, Clinical Research, Liver Diseases, in 2015. Cheng joined Gilead in 1999 to lead the company's development-stage programs in HIV/AIDS. He received additional responsibility for the company's Development Operations organization in 2009 and was named Executive Vice President in 2015. Cheng was appointed Chief Medical Officer in March.